Related references
Note: Only part of the references are listed.Rifabutin Is Active against Mycobacterium abscessus in Mice
Thomas Dick et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2020)
Repurposing drugs for treatment of Mycobacterium abscessus: a view to a kill
Tawanda Gumbo et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2020)
Rifabutin Suppresses Inducible Clarithromycin Resistance in Mycobacterium abscessus by Blocking Induction of whiB7 and erm41
Dinah Binte Aziz et al.
ANTIBIOTICS-BASEL (2020)
In Vitro Synergism of Rifabutin with Clarithromycin, Imipenem, and Tigecycline against the Mycobacterium abscessus Complex
Aristine Cheng et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
Omadacycline for Acute Bacterial Skin and Skin-Structure Infections
William O'Riordan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
In Vitro Activity of New Tetracycline Analogs Omadacycline and Eravacycline against Drug-Resistant Clinical Isolates of Mycobacterium abscessus
Amit Kaushik et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
Mycobacterium abscessus virulence traits unraveled by transcriptomic profiling in amoeba and macrophages
Violaine Dubois et al.
PLOS PATHOGENS (2019)
In Vitro Susceptibility Testing of Bedaquiline against Mycobacterium abscessus Complex
Barbara A. Brown-Elliott et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
IGNITE4: Results of a Phase 3, Randomized, Multicenter, Prospective Trial of Eravacycline vs Meropenem in the Treatment of Complicated Intraabdominal Infections
Joseph S. Solomkin et al.
CLINICAL INFECTIOUS DISEASES (2019)
Determination of MIC Distribution and Mechanisms of Decreased Susceptibility to Bedaquiline among Clinical Isolates of Mycobacterium abscessus
Bing Li et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
Tedizolid Activity Against Clinical Mycobacterium abscessus Complex Isolates-An in vitro Characterization Study
Ying Wei Tang et al.
FRONTIERS IN MICROBIOLOGY (2018)
Predominance of clarithromycin-susceptible Mycobacterium massiliense subspecies: Characterization of the Mycobacterium abscessus complex at a tertiary acute care hospital
Ka Lip Chew et al.
JOURNAL OF MEDICAL MICROBIOLOGY (2017)
British Thoracic Society guidelines for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD)
Charles S. Haworth et al.
THORAX (2017)
Assessing the Efficacy and Safety of Eravacycline vs Ertapenem in Complicated Intra-abdominal Infections in the Investigating Gram-Negative Infections Treated With Eravacycline (IGNITE 1) Trial A Randomized Clinical Trial
Joseph Solomkin et al.
JAMA SURGERY (2017)
Vancomycin and Clarithromycin Show Synergy against Mycobacterium abscessus In Vitro
Devika Mukherjee et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Comparison of Omadacycline and Tigecycline Pharmacokinetics in the Plasma, Epithelial Lining Fluid, and Alveolar Cells of Healthy Adult Subjects
Mark H. Gotfried et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Clofazimine-Containing Regimen for the Treatment of Mycobacterium abscessus Lung Disease
Bumhee Yang et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Tigecycline Is Highly Efficacious against Mycobacterium abscessus Pulmonary Disease
Beatriz E. Ferro et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
Review of Eravacycline, a Novel Fluorocycline Antibacterial Agent
George G. Zhanel et al.
DRUGS (2016)
Infections caused by Mycobacterium abscessus: epidemiology, diagnostic tools and treatment
Faiza Mougari et al.
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY (2016)
Emergence and spread of a human-transmissible multidrug-resistant nontuberculous mycobacterium
Josephine M. Bryant et al.
SCIENCE (2016)
Oritavancin: A Long-Half-Life Lipoglycopeptide
Louis D. Saravolatz et al.
CLINICAL INFECTIOUS DISEASES (2015)
Dalbavancin: A Novel Lipoglycopeptide Antibiotic with Extended Activity Against Gram-Positive Infections
Jordan R. Smith et al.
INFECTIOUS DISEASES AND THERAPY (2015)
Phase 2, Randomized, Double-Blind Study of the Efficacy and Safety of Two Dose Regimens of Eravacycline versus Ertapenem for Adult Community-Acquired Complicated Intra-Abdominal Infections
Joseph S. Solomkin et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)
Phase I, Open-Label, Safety and Pharmacokinetic Study To Assess Bronchopulmonary Disposition of Intravenous Eravacycline in Healthy Men and Women
Kevin P. Connors et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)
Clinical experience in 52 patients with tigecycline-containing regimens for salvage treatment of Mycobacterium abscessus and Mycobacterium chelonae infections
Richard J. Wallace et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2014)
A shorter treatment duration may be sufficient for patients with Mycobacterium massiliense lung disease than with Mycobacterium abscessus lung disease
Jiwon Lyu et al.
RESPIRATORY MEDICINE (2014)
Synergistic activities of tigecycline with clarithromycin or amikacin against rapidly growing mycobacteria in Taiwan
Chien-Wen Huang et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2013)
Clinical Significance of Differentiation of Mycobacterium massiliense from Mycobacterium abscessus
Won-Jung Koh et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2011)
High efficacy of clofazimine and its synergistic effect with amikacin against rapidly growing mycobacteria
Gwan-Han Shen et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2010)
Telavancin: A Novel Lipoglycopeptide
Louis D. Saravolatz et al.
CLINICAL INFECTIOUS DISEASES (2009)
Statistical characterisation of bacterial wild-type MIC value distributions and the determination of epidemiological cut-off values
J Turnidge et al.
CLINICAL MICROBIOLOGY AND INFECTION (2006)
Share Paper
